Results 111 to 120 of about 10,095 (153)

Imatinib Mesylate in Cutaneous Melanoma [PDF]

Journal of Investigative Dermatology, 2004
Redondo, Pedro, Lloret, Pedro, Andreu, Enrique J., Inoges, Susana   +3 more
openaire   +2 more sources

QbD-based co-loading of paclitaxel and imatinib mesylate by protamine-coated PLGA nanoparticles effective on breast cancer cells. [PDF]

Nanomedicine (Lond)
Laxane N, Yadav KS.
europepmc   +1 more source

Complete laparoscopic wedge resection of a giant locally advanced gastric GIST with near pathological complete response after preoperative treatment with imatinib mesylate: A case report. [PDF]

Int J Surg Case Rep, 2022
Guo H, Li Y, Wang D, Tan B, Yang P, Zhao Q.   +5 more
europepmc   +1 more source

Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model. [PDF]

In Vivo, 2021
Pinto CA, DE Sousa Portilho AJ, Barbosa MC, DE Moraes MEA, DE Lemos JAR, Burbano RMR, Moreira-Nunes CA.   +6 more
europepmc   +1 more source

MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. [PDF]

Int J Mol Sci, 2021
Martins JRB, Moraes LN, Cury SS, Capannacci J, Carvalho RF, Nogueira CR, Hokama NK, Hokama POM.   +7 more
europepmc   +1 more source

Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway. [PDF]

Bioact Mater
Pang S, Wu R, Lv W, Zou J, Li Y, Li Y, Zhang P, Ma X, Wang Y, Liu S.   +9 more
europepmc   +1 more source

Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. [PDF]

Gastrointest Tract
Marucci MA, Lechner DW, Tafuto BA.
europepmc   +1 more source

A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. [PDF]

PLoS One
Zeng L, Cheng X, Li J, Zhang J, Wu X.
europepmc   +1 more source

Multiple Eruptive Dermatofibromas Secondary to Imatinib Mesylate in a Patient with Chronic Myeloid Leukemia.

Indian J Dermatol, 2021
Lira-Valero FJ, Godínez-Aldrete L, Pulido-Díaz N, Quintal-Ramírez MJ.   +3 more
europepmc   +1 more source

Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. [PDF]

Cancers (Basel)
Boichuk S, Dunaev P, Galembikova A, Valeeva E.   +3 more
europepmc   +1 more source